306 related articles for article (PubMed ID: 32832244)
21. Spheroid-induced heterogeneity and plasticity of uveal melanoma cells.
Chen Y; Lu X; Gao L; Dean DC; Liu Y
Cell Oncol (Dordr); 2022 Apr; 45(2):309-321. PubMed ID: 35404029
[TBL] [Abstract][Full Text] [Related]
22. CD71-Specific Aptamer Conjugated with Monomethyl Auristatin E for the Treatment of Uveal Melanoma.
Zhang H; Jin C; Zhang L; Peng B; Zhang Y; Liu Y; Li L; Ye M; Xiong W; Tan W
ACS Appl Mater Interfaces; 2022 Jan; 14(1):32-40. PubMed ID: 34928139
[TBL] [Abstract][Full Text] [Related]
23. Transposase mapping identifies the genomic targets of BAP1 in uveal melanoma.
Yen M; Qi Z; Chen X; Cooper JA; Mitra RD; Onken MD
BMC Med Genomics; 2018 Nov; 11(1):97. PubMed ID: 30400891
[TBL] [Abstract][Full Text] [Related]
24. Analysis of BAP1 Germline Gene Mutation in Young Uveal Melanoma Patients.
Cebulla CM; Binkley EM; Pilarski R; Massengill JB; Rai K; Liebner DA; Marino MJ; Singh AD; Abdel-Rahman MH
Ophthalmic Genet; 2015 Jun; 36(2):126-31. PubMed ID: 25687217
[TBL] [Abstract][Full Text] [Related]
25. Chromosome 3 status combined with BAP1 and EIF1AX mutation profiles are associated with metastasis in uveal melanoma.
Ewens KG; Kanetsky PA; Richards-Yutz J; Purrazzella J; Shields CL; Ganguly T; Ganguly A
Invest Ophthalmol Vis Sci; 2014 Jun; 55(8):5160-7. PubMed ID: 24970262
[TBL] [Abstract][Full Text] [Related]
26. Stromal fibroblast growth factor 2 reduces the efficacy of bromodomain inhibitors in uveal melanoma.
Chua V; Orloff M; Teh JL; Sugase T; Liao C; Purwin TJ; Lam BQ; Terai M; Ambrosini G; Carvajal RD; Schwartz G; Sato T; Aplin AE
EMBO Mol Med; 2019 Feb; 11(2):. PubMed ID: 30610113
[TBL] [Abstract][Full Text] [Related]
27. Aggressive uveal melanoma displays a high degree of centrosome amplification, opening the door to therapeutic intervention.
Sabat-Pośpiech D; Fabian-Kolpanowicz K; Kalirai H; Kipling N; Coupland SE; Coulson JM; Fielding AB
J Pathol Clin Res; 2022 Jul; 8(4):383-394. PubMed ID: 35474453
[TBL] [Abstract][Full Text] [Related]
28. Dual inhibition of protein kinase C and p53-MDM2 or PKC and mTORC1 are novel efficient therapeutic approaches for uveal melanoma.
Carita G; Frisch-Dit-Leitz E; Dahmani A; Raymondie C; Cassoux N; Piperno-Neumann S; Némati F; Laurent C; De Koning L; Halilovic E; Jeay S; Wylie A; Emery C; Roman-Roman S; Schoumacher M; Decaudin D
Oncotarget; 2016 Jun; 7(23):33542-56. PubMed ID: 27507190
[TBL] [Abstract][Full Text] [Related]
29. Experimental therapy of doxorubicin resistant human uveal melanoma with targeted cytotoxic luteinizing hormone-releasing hormone analog (AN-152).
Oláh G; Dobos N; Vámosi G; Szabó Z; Sipos É; Fodor K; Harda K; Schally AV; Halmos G
Eur J Pharm Sci; 2018 Oct; 123():371-376. PubMed ID: 30076951
[TBL] [Abstract][Full Text] [Related]
30. Blockade of ß-Adrenergic Receptors by Nebivolol Enables Tumor Control Potential for Uveal Melanoma in 3D Tumor Spheroids and 2D Cultures.
Farhoumand LS; Liu H; Tsimpaki T; Hendgen-Cotta UB; Rassaf T; Bechrakis NE; Fiorentzis M; Berchner-Pfannschmidt U
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982966
[TBL] [Abstract][Full Text] [Related]
31. BAP1 Loss Is Associated with DNA Methylomic Repatterning in Highly Aggressive Class 2 Uveal Melanomas.
Field MG; Kuznetsov JN; Bussies PL; Cai LZ; Alawa KA; Decatur CL; Kurtenbach S; Harbour JW
Clin Cancer Res; 2019 Sep; 25(18):5663-5673. PubMed ID: 31285370
[TBL] [Abstract][Full Text] [Related]
32. Chromosomal rearrangements in uveal melanoma: Chromothripsis.
van Poppelen NM; Yavuzyigitoglu S; Smit KN; Vaarwater J; Eussen B; Brands T; Paridaens D; Kiliç E; de Klein A
Genes Chromosomes Cancer; 2018 Sep; 57(9):452-458. PubMed ID: 29726589
[TBL] [Abstract][Full Text] [Related]
33. Metastatic Disease in Polyploid Uveal Melanoma Patients Is Associated With BAP1 Mutations.
Yavuzyigitoglu S; Mensink HW; Smit KN; Vaarwater J; Verdijk RM; Beverloo B; Brüggenwirth HT; van Marion R; Dubbink HJ; Paridaens D; Naus NC; de Klein A; Kiliç E;
Invest Ophthalmol Vis Sci; 2016 Apr; 57(4):2232-9. PubMed ID: 27116551
[TBL] [Abstract][Full Text] [Related]
34. Germline BAP1 alterations in familial uveal melanoma.
Rai K; Pilarski R; Boru G; Rehman M; Saqr AH; Massengill JB; Singh A; Marino MJ; Davidorf FH; Cebulla CM; H Abdel-Rahman M
Genes Chromosomes Cancer; 2017 Feb; 56(2):168-174. PubMed ID: 27718540
[TBL] [Abstract][Full Text] [Related]
35. An image-based assay to quantify changes in proliferation and viability upon drug treatment in 3D microenvironments.
Murali VS; Chang BJ; Fiolka R; Danuser G; Cobanoglu MC; Welf ES
BMC Cancer; 2019 May; 19(1):502. PubMed ID: 31138163
[TBL] [Abstract][Full Text] [Related]
36. Hereditary uveal melanoma: a report of a germline mutation in BAP1.
Höiom V; Edsgärd D; Helgadottir H; Eriksson H; All-Ericsson C; Tuominen R; Ivanova I; Lundeberg J; Emanuelsson O; Hansson J
Genes Chromosomes Cancer; 2013 Apr; 52(4):378-84. PubMed ID: 23341325
[TBL] [Abstract][Full Text] [Related]
37. BAP1 germline mutation in two first grade family members with uveal melanoma.
Maerker DA; Zeschnigk M; Nelles J; Lohmann DR; Worm K; Bosserhoff AK; Krupar R; Jägle H
Br J Ophthalmol; 2014 Feb; 98(2):224-7. PubMed ID: 24187051
[TBL] [Abstract][Full Text] [Related]
38. The antihelminthic drug niclosamide effectively inhibits the malignant phenotypes of uveal melanoma
Zhou J; Jin B; Jin Y; Liu Y; Pan J
Theranostics; 2017; 7(6):1447-1462. PubMed ID: 28529629
[TBL] [Abstract][Full Text] [Related]
39. Uveal melanoma cell lines contain stem-like cells that self-renew, produce differentiated progeny, and survive chemotherapy.
Kalirai H; Damato BE; Coupland SE
Invest Ophthalmol Vis Sci; 2011 Oct; 52(11):8458-66. PubMed ID: 21896849
[TBL] [Abstract][Full Text] [Related]
40. Uveal melanoma cell lines Mel270 and 92.1 exhibit a mesenchymal phenotype and sensitivity to the cytostatic effects of transforming growth factor beta in vitro.
Doudnikoff C; Leclerc D; Angenard G; Gilot D; Coulouarn C; Mouriaux F
Mol Vis; 2024; 30():160-166. PubMed ID: 38601020
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
